How much funding has Cytospire Therapeutics raised?

Cytospire Therapeutics has raised $182.0M in total funding, most recently a Series A round.

Who are Cytospire Therapeutics's investors?

Cytospire Therapeutics's investors include 4BIO Capital, Servier Ventures, British Business Bank, Sound Bioventures, Criteria Bio Ventures, LifeArc.

When was Cytospire Therapeutics founded?

Cytospire Therapeutics was founded in 2023.

Where is Cytospire Therapeutics headquartered?

Cytospire Therapeutics is headquartered in London, United States.

What industry is Cytospire Therapeutics in?

Cytospire Therapeutics operates in Biotech, Healthcare.

How many employees does Cytospire Therapeutics have?

Cytospire Therapeutics has 11-50 employees.

Cytospire Therapeutics

Next generation immune cell engagers for cancer

London, United States · Founded 2023 · $182.0M raised

Biotech

Healthcare

Headquarters: London
Employees: 11–50
Founded: 2023
Business Model: B2B

Website: cytospire.com
Total Funding: $182.0M
Last Round: $99.0M Series AMay 2026
Rounds: 2

About

Cytospire Therapeutics is a UK-based clinical-stage biotechnology company developing next-generation multispecific immune cell engagers for cancer treatment. Its lead programs are pan-gamma delta (γδ) T cell engagers designed to direct the innate and adaptive immune system against tumors, offering a safer and more tailored alternative to CD3-based engagers. The company was founded by leadership previously at Adaptate Biotherapeutics and GammaDelta Therapeutics, both acquired by Takeda Pharmaceuticals, and raised an oversubscribed £61 million ($83M) Series A in May 2026 led by 4BIO Capital.

Summary

Cytospire Therapeutics is a Biotech company based in London, United States, founded in 2023. It has raised $182.0M in total across 2 rounds, most recently a $99.0M Series A round in May 2026. Investors include 4BIO Capital, Servier Ventures and British Business Bank.